Merck & Co Inc

NYSE:MRK   10:14:28 AM EDT
-0.42 (-0.52%)

Merck Says FDA Accepts Submission Of sNDA For Lynparza As Treatment Breast Cancer, Grants Priority Review

Published: 11/30/2021 12:53 GMT
Merck & Co Inc (MRK) - FDA Accepts Regulatory Submission of Supplemental New Drug Application for Lynparza® (olaparib) As Adjuvant Treatment in Brca-mutated, Her2-negative High-risk Early Breast Cancer and Grants Priority Review.